# Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

> **NCT00138060** · PHASE4 · COMPLETED · sponsor: **Institut de Recherche Clinique sur les Cancers et le Sang** · enrollment: 71 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** irinotecan
- **DRUG:** 5 fluorouracil

## Key facts

- **NCT ID:** NCT00138060
- **Lead sponsor:** Institut de Recherche Clinique sur les Cancers et le Sang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2010-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138060, "Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00138060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*